2017 marks 200 years since James Parkinson's published his 'Essay on the Shaking Palsy'. Although now most famous for describing the condition that came to bear his name, Parkinson had a wide range of interests and his influence spread beyond medicine. In this review, we provide a biography of James Parkinson's remarkable life. Parkinson's paper not only comprehensively described the symptoms of Parkinson's disease (PD), but challenged his peers to better understand the pathophysiology of the PD. Key observation over the next 2 centuries, included the recognition of the link between the substantia nigra and PD and the discoveries of dopamine deficiency in patients with PD. We review the subsequent development of pharmacological and surgical therapies. Despite great progress over the last 200 years, Parkinson's hopes for a 'cure if employed early enough' or that 'some remedial process may ere long be discovered by which at least the progression of the disease may be stopped' remain apposite today and we reflect on the challenges ahead for the next century.
Introduction
2017 marks the 200th anniversary since the publication of James Parkinson's 'Essay on the shaking Palsy' [1] . Though he described just six individuals, Parkinson recognised the characteristic diagnostic features of the condition that came to bear his name.
Prior to his paper, physicians of the time considered the cardinal signs of Parkinson's disease (PD) as separate diseases [2, 3]. Parkinson described a single, progressive disorder and hoped that his description would inspire his peers to understand the pathology underlying the disorder and in turn find therapies. Over the last 2 centuries, advances in the understanding of the pathology underlying PD have led to improved treatment, but progress has been slow and sadly, Parkinson's hopes for disease modifying agents remain elusive. In his original description of the disease Parkinson recognised the importance of carers and recognised the physician's wider social responsibility beyond medicine.
In this review, we will examine who Parkinson was, how his initial description of his eponymous condition has stood the test of time, and how the development of an understanding of the pathology underlying the disease led to our current therapies. We will conclude by examining what Parkinson could teach us about the wider role of the PD physician working today.
Who was James Parkinson?
Born in London in 1755, James Parkinson was a polymath whose interests included palaeontology, geology and politics. Under the pseudonym 'Old Hubert' he was a leading campaigner for social reform and was an advocate for the underprivileged and universal suffrage [4] . In 1784, he was approved as a surgeon-apothecary by the City of London Corporation.
Parkinson, a social reformer and a critic of Pitt's government, joined the secret political reformist group the London Corresponding Society (LCS). In 1794, five members of the LCS were implicated in a sham conspiracy to assassinate King George III with a 'pop-gun', a form of poisoned dart [5] . Parkinson was called as a witness for the defence. The so-called 'conspirators' were eventually freed. Disillusioned by this experience, Parkinson effectively retired from his political life and focused his energies on medicine, publishing several medical papers. The most famous of these was the 'Essay on the Shaking Palsy' published in 1817 [1] .
The Shaking Palsy
The essay is a descriptive study [1] in which Parkinson systematically describes a syndrome he had observed in six individuals (three patients, two people he met in the street and one who he had observed at a distance). He noted the degenerative nature of the disease and described the classic parkinsonian posture, festinant gait, and the typical character and spread of the tremor. Understanding of tremors at the time was limited, crossing over with other conditions such as seizures. Parkinson termed this syndrome the 'Shaking Palsy' or 'Paralysis Agitans'.
It is now well recognised that non-motor symptoms including sleep-wake dysregulation, cognitive dysfunction, mood disturbance, dysautonomia and pain, may be present in all stages of PD and have major impact on quality of life [6, 7] . These symptoms, were however, largely overlooked in many of the key texts of the last the last two centuries. It is therefore of particular note that Parkinson recognised the significance of non-motor symptoms in his paper and his original descriptions are shown in Table 1 . Five decades after the publication of the Shaking Palsy Jean-Martin Charcot first used the term 'Maladie de Parkinson' to describe a disorder characterised by rest tremor, rigidity, facial immobility and a disturbed gait and posture [3] . In 2017, PD as the condition is now known, remains largely a clinical diagnosis and it is noteworthy that Parkinson described so many of the cardinal features that form the diagnostic criteria used today [8, 9] .
The pathology of PD
Parkinson hoped that the publication of the shaking palsy would inspire others to investigate the pathology underlying the syndrome and, that this in turn, would result in therapy.
'That these friends to humanity and medical science, who have already unveiled to us many of the morbid process by which health and life is abridged, might be excited to extend their research to this malady was much desired and it was hoped that this might be produced by the publication of these remarks.'
'…having excited the attention of those, who may point out the most appropriate means of relieving a tedious and most distressing malady' [1] .
In 1893, Blocq and Marinesco suggested a link between pathology in the substantia nigra and the condition by then known as PD [10] . The insight came from a tuberculous patient admitted to Charcot's neurology ward who was suffering from a unilateral parkinsonian tremor [11] . At autopsy, Blocq and Marinesco discovered an isolated tumour in the substantia nigra contralateral to the tremor. Freidrich Heinrich Lewy was the first describe the characteristic intraneuronal inclusion bodies in the dorsal motor nucleus of the vagus nerve, the basal nucleus of Meynert, the globus pallidus, the lateral nucleus of the thalamus, and the periventricular nucleus of the thalamus [12] . In 1919, Tretiakoff, a Russian neuropathologist who coined the term 'corps de Lewy' (Lewy bodies), reported the presence of these inclusions in the substantia nigra of patients with idiopathic and post-encephalitic Parkinsonism [11, 13] .
In the late 1950s, Arvid Carlsson and colleagues noted drug-induced Parkinsonism in animals exposed to the sedating dopamine antagonist, reserpine. Carlsson [14] found that DOPA (the precursor of dopamine) dramatically alleviated Parkinsonism. Until this time dopamine was thought to be purely a precursor in the synthesis of noradrenaline. The group developed a stain to measure dopamine levels and demonstrated high dopamine concentrations in the striatum of animals [14] . Carlsson proposed that dopamine was itself a neurotransmitter, implicated in motor control. Bertler and Rosengren [15] confirmed that dopamine was most prevalent in the basal ganglia in a wide range of animals. Having read Bertler and Rosengren's paper, Hornykiewicz, working in Oxford, England, demonstrated the absence of dopamine in six patients with parkinsonism (four post-encephalitic and two PD) [16, 17] .
Development of the treatment of PD Pharmacological
Prior to Carlsson and Hornykiewicz's work, antimuscarinic alkaloids remained the only treatment option for PD. Belladonna alkaloids, initially administered to control sialorrhea, were the first pharmacological agent found to control tremor [16] . In the 1940s, the first synthetic anticholinergic drugs became available and in 1949 Trihexyphenidyl was marketed for PD [18] .
Parkinson's hopes that an understanding of the pathology underlying PD would lead to effective therapy began to materialise in the second half of the 20th century. Having demonstrated decreased dopamine in the striatum of Parkinsonian patients, Hornykiewicz suggested that dopamine may alleviate Parkinsonism. Hornykiewicz recognised that dopamine would not cross the blood brain barrier but that the precursor DOPA would. Hornykiewicz found most neurologists to be skeptical about the role of DOPA. Surgical techniques were under development for Parkinson's and neurologists of the time thought it unlikely that a neurodegenerative condition could be reversed by a single neurotransmitter. Hornykiewicz approached Walther
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Birkmayer (a physician in charge of the largest Municipal Home for the Aged in Vienna). Overall, 20 volunteers with PD were injected with 50-150 mg of intravenous (IV) DOPA. Birkmayer and Hornykiewicz reported a single dose resulted in complete abolition of akinesia and restoration of function [17] . Simultaneously in 1961, Barbeau saw short lasting improvements in akinesia with oral L-DOPA but not D-DOPA [19] . Several subsequent studies with low doses of oral and IV DOPA showed mixed results and neurologists remained skeptical that L-DOPA was a practical treatment or even if it was more effective than placebo [20] .
A key breakthrough came in 1967 when George Cotzais gave patients repeated, large, daily doses of a racemic mix of D-L dopa. This proved highly effective and results could be sustained [21] . However, intolerable gastrointestinal and haematological side effects hampered this approach. Limiting DOPA to the physiologically active L-enantiomer halved the dose required and reduced haematological adverse effects [17] . George Cotzais discovered that by gradually increasing the dose of L-DOPA it was possible to reduce the adverse gastrointestinal effects [21] .
In 1967, dopamine decarboxylase (DDC) inhibitors were found to increase bioavailability of levodopa [22] . DDC inhibitors enhance levodopa absorption from the intestine, prevent its decarboxylation in the peripheral tissues and inactivate the brain capillary enzymatic barrier to levodopa [16] . DDC inhibitors do not cross the blood brain barrier, when administered with L-DOPA they increase the peripheral half-life by about 90 min and reduce the therapeutic dose of L-DOPA by 60-80% [23] . Combination treatment of Levodopa and DDC inhibitors dramatically reduced gastrointestinal and cardiac side effects [23] .
Yahr, a neurologist initially skeptical about the therapeutic usefulness of L-DOPA, recognised the importance of Cotzias' work and the need for double-blind controlled trials. Yahr et al. [24] published the first randomised controlled trial demonstrating the efficacy of L-DOPA and L-DOPA-DDC combination was approved by the American Food and Drug Administration in 1970. L-DOPA remains the gold standard pharmacological treatment for PD and the successful drug developments over the last 60 years have focused on increasing the bioavailability of L-DOPA or mimicking its effects with dopamine agonists (Figure 1 ).
Surgery
Like the pharmacological treatments for PD, surgical interventions have fallen in and out of favour and establishing their place in the armoury of PD therapeutics has taken several decades. Several groups attempted to use lesioning to control tremor. Initial attempts settled tremor at the expense of paralysis [16] , however, in 1961, Irving Cooper accidently discovered that ligation of the anterior choroidal artery abolished tremor without causing paralysis. Cooper defined specific regions to be targeted to reduce tremor. This observation and early reports of benefits with lesions of the pallidum, led to the development of pallidotomy as a neurosurgical treatment for PD. Further work by Hassler, who defined the pallidothalamic projections, led to the development of thalamotomy for PD [25] . However, by the end of the 1960s, neurosurgical approaches were over shadowed by the arrival of L-dopa. By the 1970s, although thalamotomy was occasionally used for drug refractory tremor advancements of surgical techniques for managing PD had stalled.
In 1987, two groups simultaneously reported beneficial results for Parkinson's tremor from non-lesioning approaches through high frequency thalamic stimulation [26] . In the 1990s, primate models revealed the role of the globus pallidus interna (Gpi) and subthalamic nucleus (STN) circuitry changes associated with akinesis in Parkinson's. Over subsequent years numerous reports suggesting beneficial effects of internal Gpi and STN stimulation were published and these remain the two targets most commonly used today.
Since the 1980s cell-based and gene-based surgical therapies have been under investigation. Cell therapies have reached the proof of concept stage and have recently been comprehensively reviewed by Barker et al. [27] . Long-term efficacy and safety of these therapies remain to be established and like current therapies for PD, these interventions would be focused at providing symptomatic relief by relieving dopaminergic deficiencies. 
Sleep
'In this stage, the sleep becomes much disturbed. The tremulous motion of the limbs occur during sleep, and augment until they awaken the patient, and frequently with much agitation and alarm' Constipation 'The bowels, which had been all along torpid, now, in most cases, demand stimulating medicines of very considerable power: the expulsion of the faeces from the rectum sometimes requiring mechanical aid…' Speech disturbance 'His words are now scarcely intelligible' Dysphagia '…and he is not only no longer able to feed himself, but when the food is conveyed to the mouth, so much are the actions of the muscles of the tongue, pharynx, impeded by impaired action and perpetual agitation, that the food is with difficulty retained in the month until masticated; and then as difficultly swallowed.' Sialorrhea 'the saliva fails of being directed to the back part of the fauces, and hence is continually draining from the mouth' Incontinence 'The urine and faeces are passed involuntarily'
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Pathological progression of PD and neuroprotective therapies
Although lesions in the substantia nigra remain the pathological hallmark of PD, Heiko Braak's work suggested that the pathology spreads by cell to cell contact. It is postulated that pathology spreads from the periphery into the medulla and olfactory system (causing autonomic and olfactory deficits), progressing further into the brainstem and basal ganglia (causing sleep and motor disturbance) and ultimately progressing to the limbic system and cortex (causing behavioural symptoms and cognitive dysfunction) [28] . The Braak hypothesis suggests a progression of PD from those who have Lewy pathology without clinical features of PD, to those with end-stage disease and raises the hope of, as Parkinson himself suggested:
'some remedial process may ere long be discovered by which at least the progression of the disease may be stopped'.
Sadly, convincing disease modifying therapies remain elusive. An extensive list of agents have been tested [29] . Drugs without dopaminergic effect have been unsuccessful. Those with dopaminergic effect are probably effective by masking symptoms rather than actually modifying disease progression. Furthermore, the majority of clinical trials of potential disease modifying agents have been performed in patients with established PD. In these groups, the majority of dopaminergic neurons have been lost potentially meaning that by the time the clinical trial is performed it is too late. Parkinson noted that interventions would only be expected to provide, 'cure if employed early enough'.
In 2017, National Institute of Health and Care Excellence (NICE) published updated guidelines for the management of PD in Adults [30] . 200 Years after Parkinson first described PD, there is still no proven disease modifying agent and therapy remains focused on relieving symptoms and improving quality of life.
Providing holistic care in PD James Parkinson was a strong believer in the role of medicine to go beyond treating the disease and recognised the importance of holistic care. Given the constellation of symptoms seen in PD the condition has previously been referred to as a 'geriatric syndrome' [31] . It therefore follows that management of the condition may well be suited to an approach analogous to the Comprehensive Geriatric Assessment employed by geriatricians [32] . The skill-set of a geriatrician, along with the wider multidisciplinary team, may be particularly valuable as PD reaches the complex phase, where the burden of neuropsychiatric and non-motor complications is high. Furthermore, geriatricians have expertise in end of life care. As PD progresses towards the palliative phase, geriatricians 
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often have a central role in ensuring patients' autonomy is preserved and that potentially difficult conversations about advanced care planning are undertaken at the appropriate stage in the condition.
Many people with complex PD will require care from either an informal carer (e.g. wife/husband/family) or formal (paid) carers within their own home as their condition progresses, due to complex symptoms and increasing levels of disability. Over the last 25 years there have been an increasing number of studies involving carers for people with PD. A recent study found that the median time spent as a carer was 5 years (interquartile range: 3-10) and the median number of hours spent caring per day was 16, demonstrating the significant role that carers play in supporting people with Parkinson's to remain at home [33] . There have been a number of studies demonstrating significant carer burden among carers for a people with PD [34, 35] .
Parkinson recognised the importance of carers in his original description of the disease and made reference to the need for support with activities of daily living.
'The patient walks now with great difficulty, and unable any longer to support himself with his stick, he dares not venture on this exercise, unless assisted by an attendant, who walking backwards before him, prevents his falling forwards, by the pressure of his hands against the fore part of his shoulders.' 'The power of conveying the food to the mouth is at length so much impeded that he is obliged to consent to be fed by others'.
What would Parkinson the social reformer think?
Parkinson was a social reformer writing under the nom de plume 'Old Herbit' he campaigned for the rights of 'lunatics', children, and older people. Age is the strongest risk factor for PD. Worldwide prevalence of PD per 100,000 is 41 at 40-49 years compared to 428 at 60-69 years; and 1,903 in those older than 80 years [36] . 200 Years ago, when Parkinson wrote the Shaking Palsy, average life expectancy at birth in the UK was less than 45 years. For a women born in the UK 2010, this is now 82 years. In recent years life expectancy has also begun to increase in the developing world resulting in an increased burden of chronic disease. Traditionally healthcare systems in the developing world have been focused on managing communicable disease in younger populations. As their populations age the need to manage chronic disease in an ageing population will present an increasing challenge. Dorsey et al. have projected that the number of individuals living with PD will more than double between 2005 and 2030, and that the population of PD patients is set to become increasingly concentrated in the developing world [37] .
Health services in the developing world are poorly prepared to cope with these transitions and amid the enduring need for infectious disease services there is poor access to specialist neurological or geriatric services. Consistent access to affordable drug treatments for PD also remains a challenge [38] . In most places, L-dopa, anticholinergics and occasionally Bromocriptine, are not always consistently available and are rarely affordable for the majority. A door-to-door prevalence study in Northern Tanzania [38] , found that less than a quarter of the patients identified as having PD had previously been diagnosed and even fewer were on regular drug treatment. It is therefore likely that half the people in the world with PD are not diagnosed, and consequently have a much reduced life expectancy, not too dissimilar to the times of James Parkinson. More priority must be given to improving education among health professionals in the developing world and ensuring access to available and affordable drug treatment [39] .
Conclusion
200 Years after the publication of the Shaking Palsy provides an apt time to pause and reflect on Parkinson and his observations. Even with the array of tools available to modern medicine the diagnosis remains a clinical one and many of the features Parkinson described continue to underpin the diagnostic process [9] . Without a cure or a disease modifying agent, demographic changes alone mean the burden of PD is set to increase dramatically over the next 200 years. There are few conditions where the treatment of symptoms is as personalised as in PD, which mandates a delicate balance between controlling symptoms, balancing drug treatment with side effects, responding to patients' wishes and managing expectations. It can be considered a perfect illustration of where medicine the art, meets medicine the science. Parkinson's publications also remind us of the importance of empathy with our patients. 200 Years on, Parkinson's conclusions remain as relevant as ever and thus it seems fitting to end this article as he ended his.
'Before concluding these pages, it may be proper to observe once more, that an important object proposed to be obtained by them is, the leading of the attention of those who humanely employ anatomical examination in detecting the causes and nature of diseases, particularly to this malady. By their benevolent labours its real nature may be ascertained, and appropriate modes of relief, or even of cure, pointed out'.
Key points
• 200 Years ago James Parkinson comprehensively described the motor and non-motor features Parkinson's disease (PD).
• The resulting growth in understanding of the pathophysiology of PD has resulted in better treatment for PD.
• Age is the greatest risk factor for Parkinson's disease.
• Increasing life expectancy in the developing world means that the population of PD patients is set to become increasingly concentrated in the developing world.
• Patients with Parkinson's disease benefit from a Comprehensive Geriatric Assessment.
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